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Adele K. FieldingINTRODUCTION
Acute lymphoblastic leukemia (ALL) in which the
chromosome translocation t(9;22)—known as the
Philadelphia (Ph) chromosome—is detected has been
associated with a considerably lower rate of complete
remission (CR) and a lower long-term overall survival
(OS) than in Philadelphia negative disease. Ph1 ALL
accounts for approximately one-quarter of all adult
ALL [1] but only about 2% of ALL in children [2].
Clinical trials have typically assigned patients with
this form of ALL to ‘‘very high-risk’’ treatment arms
and outside of a clinical trial, most physicians would
recommend myeloablative hematopoietic stem cell
transplant (HSCT) for adult patients in CR where
a matched sibling or unrelated donor is available.
However, with the advent of tyrosine kinase inhibitors,
there is the possibility to target therapy more precisely
by inhibiting the function of the oncogenic protein
products of one or more of the genetic lesions involved
in this disease using tyrosine kinase inhibitors. Numer-
ous studies have now reported on the use of the selec-
tive tyrosine kinase inhibitor (TKI) imatinib in de
novo Ph1 ALL. Some studies are also beginning to
report outcomes of using dasatinib, a TKI that also in-
hibits Src kinase activity. In children, where the out-
come of treatment for ALL is much better than that
in adults in addition, the long-term consequences of
allogeneic HSCT have a greater impact. Hence, there
is already increasing reluctance to offer allogeneic
HSCT to children in the ‘‘TKI era,’’ but do the data
fully substantiate this approach? In this article I will
interrogate published evidence to address the question
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A HISTORIC PERSPECTIVE: BENEFITS OF
MYELOABLATIVE ALLOGENEIC STEM CELL
TRANSPLANT IN PH1 ALL IN THE
‘‘PRETYROSINE KINASE INHIBITOR’’ ERA
All studies reporting outcomes of myeloablative
sibling allogeneicHSCT in adults with ALL published
to date conclude that, in selected individuals with the
disease, disease-free survival (DFS) and OS are better
than would be expected had patients been treated
with chemotherapy alone [3-7]. However, many of
them were nonrandomized ‘‘transplant-only’’ studies
reporting only outcomes on series of patients who
underwent the procedure—none of them included
a control group that did not receive a transplant.
Stronger support for the overall benefit of sibling
alloHSCT in unselected patients with Ph1 ALL
comes from the two largest studies conducted in this
disease. The LALA-94 trial [3] prospectively studied
154 patients with Ph1 ALL and showed that among
103 patients eligible for HSCT, the existence of a sib-
ling allogeneic donor was independently predictive of
remission duration. The UKALL12/E2993 study [8]
examined an outcome of 267 patients with Ph1 ALL
in the preimatinib era. An unrelated donor was permis-
sible if no sibling donor was available. An analysis of
treatment received showed that patients who received
myeloablative sibling allogeneic HSCT had a much
better outcome than those receiving chemotherapy
alone—the same was true for those receiving unrelated
donor HSCT. However, the overall rate of stem cell
transplantation was relatively low—fewer than 28%
of the study population were able to reach allogeneic
HSCT. The main reason for this was older age or dis-
ease resistance or relapse.
In high-risk ALL, matched unrelated donors
(MUD) have long been used as sources of stem cells
when sibling donors are unavailable, and there is evi-
dence that a well-MUD HSCT is commensurate
with that of a sibling HSCT. In a single-center study
of 84 patients with high-risk ALL (not all of which
were Ph1), where a considerable proportion were
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a TBI-based conditioning regimen, did not differ sig-
nificantly between sibling and unrelated donor stem
cells. However, the median age of patients was only
23 years and the population included children [9]. A
larger study including 72 patients with Ph1 disease
and an older median age [10] also showed equivalent
(equally high) treatment-related mortality (TRM) be-
tween matched sibling (43%) and unrelated donor
HSCT (50%). Again, patients beyond CR1 were in-
cluded—an obvious adverse influence on treatment
morbidity and mortality. Another retrospective study
of patients with poor risk ALL, 97 of whom were
Ph1, a very high TRM of 54%was reported but bal-
anced against a 6% relapse among patients trans-
planted in CR1, there was a relatively respectable
37% DFS. This compared favorably with DFS after
treatment with chemotherapy alone and was equiva-
lent to outcomes recorded following HLA-identical
sibling transplantation [11].
In childhood ALL, t(9,22) remains an indication
for HSCT. However, due to the rarity of the disease
studies have been hard to carry out. A German (BFM)
and Italian (AIEOP) study of 61 children confirmed
the superiority of sibling alloHSCT over chemother-
apy alone with a good early response to steroid being
crucially predictive of outcome [12]. In a large, inter-
national cooperative study of 326 children involving
10 study groups or large single institutions, the differ-
ence in outcome between sibling HSCT—where al-
most three-quarters of patients were long-term
disease-free survivors, and chemotherapy where only
one-quarter of patients survived long term—was fur-
ther evidence in favor of sibling allogeneic HSCT in
children [13]. However, in that study, the evidence
supporting unrelated donor transplants in children
with Ph1 ALL was less persuasive. A 43% TRM, al-
though comparable to that seen in adult studies at the
time, did not result in a survival advantage to MUD
HSCT because of the better outcome with chemo-
therapy alone in children compared to adults. It is
worth noting that among the survivors of MUD
HSCT, the relapse rate was very low, at 19%. As a re-
sult of these data there is a reluctance to expose chil-
dren to the morbidity and mortality of an unrelated
donor HSCT.
Taken together, the weight of evidence in the
pre-TKI era has been interpreted in favor of myeloa-
blative HSCT using either a sibling or unrelated
donor in CR1 in adults with Ph1 ALL and in favor
of sibling myeloablative HSCT in children in CR1
with Ph1 ALL.
Nonmyeloablative Transplant in Ph1 ALL
No prospective studies of transplant using
reduced-intensity conditioning (RIC) have been re-
ported to date. Hence, published reports are subjectto considerable bias as described below. To compound
difficulty in interpretation of the data, most series
include patients beyond CR1. The EBMT reported
97 patients who received a variety of different RIC reg-
imens, many of which were delivered in conjunction
with some form of T cell depletion [14]. A 2-year OS
of 52% for those transplanted in CR1 was reported.
A German multicenter study examined the outcome
of a very mixed group of 22 patients with high-risk
ALL receiving nonmyeloablative allogeneic HSCT
[15], 11 of whom had Ph1 disease. Half were beyond
CR1. Few patients survived long term and mortality
was high, but for many, this was a second HSCT after
relapse making a good outcome very unlikely. Another
retrospective study included 27 patients from 4 differ-
ent studies who had undergone nonmyeloablative allo-
geneic HSCT [16]. More than 80% of the patients
whose median age was 50 years were beyond CR1.
Two year OS was 31%. TRM was relatively modest
(23%) for such a high-risk population. A City of
Hope series [17] reported on 24 adult patients with
high-risk ALL treated with fludarabine and melphalan
conditioning without T cell depletion. Nearly half
of the patients were over 50 years of age. There was
a 2-year OS and DFS of 61.5% with a TRM of
21.5%. Bachanova and colleagues [18] reported
a 3-year OS of 50% among 22 patients with a median
age of 49 years, all with high-risk ALL. Patients re-
ceived a uniform reduced-intensity approach of fludar-
abine, cyclophosphamide, and low-dose total-body
irridiation (TBI) in the University of Minnesota
Transplant Program. Nonmyeloablative allogeneic
HSCT approaches are promising but require careful
prospective studies to define their role in Ph 1 ALL.
The forthcoming study from the UKNational Cancer
Research Institute Group, UKALL14 will assign all
patients with ALL aged 40 or over to a nonmyeloabla-
tive approach with fludarabine, melphalan, and alem-
tuzumab in an attempt to reduce the very high
incidence of graft-versus-host disease (GVHD)
(86%) that occurred in the City of Hope where
fludarabine and melphalan was used without T cell
depletion.
Difficulties in Evaluation of the Role of HSCT in
Ph1 ALL
Before considering the impact of TKIs on the role
and outcome of HSCT in Ph1 ALL, it is worth
pausing to note the problems with interpreting the
evidence regarding of the role of myeloablative
HSCT in this disease.
Equipoise in trial design has forestalled trials in-
cluding a randomization of allograft versus chemo-
therapy. Hence, the most straightforward method of
obtaining a relatively unbiased, prospective view of the
contribution of HSCT to outcome has been the so-
called ‘‘biologic randomization.’’ An intention-to-treat
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a matched sibling donor—assumed to be a random oc-
currence—can control for the main sources of bias in
analyzing transplant outcomes as long as the analysis
is confined to patients who were all tissue typed pro-
spectively at the time point of having an apparent equal
chance to have a transplant in the future, with sibling
donor availability being taken as the only deciding fac-
tor. However, the increasing availability of alternative
donors means that a great many of those without a sib-
ling donor can nonetheless receive an allograft. This
means that very careful analysis and scrutiny of data
are required to make a firm conclusion about the
benefits of myeloablative allogeneic HSCT. The 2
main problems to be aware of are selection bias and
immortal time bias.
In retrospective studies, a strong selection bias is
often at work. This is a particular problem for retro-
spective ‘‘transplant-only’’ studies, which report on
the outcome of patients who have already received
HSCT. Patients considered by their physicians to be
unsuitable candidates by virtue of advancing age,
poor performance status, or lack of desire to undergo
the procedure will simply not be referred for this ther-
apy, and their outcome is not taken into account in
such studies.
In prospective studies, there is an additional prob-
lem in interpreting data resulting from ‘‘survivor treat-
ment selection bias,’’ also known as ‘‘immortal time
bias.’’ In essence, a patient with Ph1 ALL on a pro-
spective study who receives a transplant is guaranteed
to have achieved—and have remained in—CRbetween
presentation and to have survived induction and subse-
quent therapy, resulting in a period of ‘‘immortal
time.’’ Clearly, a patient who has died either of disease
or treatment-related causes within the immortal time
window could not have received a transplant, resulting
in an immortal time bias. This bias is very strong in
studies of Ph1 ALL because of the lower rates of
CR than in Ph2 ALL, the tendency for short remis-
sion duration, and the toxicity of initial therapy.
Data can be analyzed with a view to attempt to
control for an immortal time bias which means,
pragmatically, when comparing the outcome of che-
motherapy alone with the outcome of transplant in
Ph1 ALL it is necessary to eliminate from the analyses
all chemotherapy-treated subjects who did not have an
equal chance of reaching HSCT, for example, those
who are beyond the upper age limit, unfit because of
comorbid conditions, or who have relapsed before
transplant. A good example of how the potential
benefits of HSCT to a population of patients present-
ing with Ph1 ALL can be overestimated by a simple
analysis of treatment received is provided by the
UKALL12/ECOG 2993 trial [8]. Analysis by treat-
ment received showed that those who received sibling
or MUD HSCT had a much better 5-year OS (44%and 36%) than those receiving chemotherapy whose
survival was only 19% at 5 years. These differ-
ences—and differences in event-free survival (EFS)
and relapse-free survival (RFS)—were highly statisti-
cally significant. However, when the analysis was
repeated adjusting for age, gender, and presenting
white blood cell count (WBC) and chemotherapy-
treated patients who relapsed or died before the me-
dian time to transplant were excluded, only relapse
free survival remained significantly superior in the
transplanted group.Do the Benefits of Tyrosine Kinase Inhibitors in
Ph1 ALL Render Allogeneic Transplant
Obsolete?
Having reviewed the data on bone marrow trans-
plantation in the ‘‘pre-imatinib’’ era, we can conclude
that, in patients who achieve remission, are sufficiently
fit, young, and have a donor, transplant appears to be
the optimal postremission therapy. Therefore, impor-
tant questions regarding TKI, by far the most studied
of which is imatinib, are
1. Is there a higher rate of complete remission without
additional toxicity when TKI are added to therapy?
2. Do more patients receive HSCT when TKI is
added to therapy?
3. Is there a survival advantage to receiving TKI?
4. Does this survival advantage occur in the absence of
HSCT?
Questions 1 and 2 have been adequately answered
by numerous large studies represented in Table 1. To
summarize the data from studies in Table 1, rates of
complete remission are considerably higher than
seen in Ph1 ALL in the past and now easily reach
and often exceed those attained in Ph2 ALL because
TKI can result in CR with minimal induction mortal-
ity. Consequently, transplant rates appear much
higher than in preimatinib studies.
The third question, whether there is a survival ben-
efit to TKI therapy, is slightly harder to answer from
current published data, because many of the studies
report results with short follow-up and include only
historic controls. However, emerging evidence is
increasingly suggestive of improved long-term out-
comes. A recent Italian study [19] included 94 patients
35 of whom were a (nonrandomized) control group
who did not receive imatinib. The patients who re-
ceived imatinib had a statistically significant improve-
ment in 5-year OS—38% versus 23% for those who
did not receive the drug. However, the largest study
of TKI in Ph1 ALL adults is the UKALL12/
ECOG2993 study, which has recently been reported
in abstract form. The existence of a very large historic
control group treated on the same study prior to ima-
tinib facilitates a reasonable estimate of long-term
Table 1. Studies of Imatinib in Ph+ ALL
Author/Year Study Group N CR (%)
Transplant
Rate (%) Overall Survival
Published studies
Thomas et al., 2004 [24] MD Anderson 20 93 50 75% at 20 months
Yanada et al., 2006 [25] Japanese Adult Leukemia Study Group 80 96 61 75% at I year
Wassmann et al., 2006 [26] German Multicenter ALL group 92 95 77 36% (alternating schedule) 43%
(concurrent schedule at 2 years
De Labarathe et al.,
2007 [27]
GRAALL 45 96 48 65% at 18 months
Vignetti et al., 2007 [22] GIMEMA 30 100 N/A 74% at 12 months
Ottman et al., 2007 [25] GMALL 55 96 (imatinib)
50 (chemo)
N/A 42% at 24 months
Ribera et al., 2009 [28] PETHEMA 30 90 70 30% at 4 years
Bassan et al., 2010 [17] Northern Italian Leukemia Group 59 92 63 38% at 5 years
Schultz et al., 2009 [20] Children’s Oncology Group 92 Not stated N/A 80% (EFS) at 3 years
Fielding et al., 2010 [21] UK National Cancer Research Institute,
Eastern Co-operative Oncology Group
145 95 44 43% at 3 years
Chalandon et al., [29] GRAALL 188 100 (imatinib DIV)
96 (imatinib hyper-CVAD)
62 62% at 2 years
EFS indicates event-free survival; CVAD, central venous access device.
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attributable difference in all outcome measures with
OS improving from 23% in the preimatinib era to
43% when imatinib was given.
The final question of whether the potential sur-
vival benefit ensuing from TKI therapy can occur in
the absence ofHSCT is amuchmore difficult question
to answer, because most studies automatically assign
patients to allograft wherever possible. Among the
few published studies to report upon the outcome of
a substantial group of patients of ‘‘transplantable
age’’ who did not receive transplant was the ALL202
trial from the Japanese Adult Leukemia Study Group
trial in which the combination of imatinib and chemo-
therapy was evaluated in 80 adult patients, 31 of whom
did not undergo alloHSCT. When compared to his-
toric controls in whom there were no event-free survi-
vors at 24 months, the 2-year estimated EFS was
significantly better for those receiving imatinib as
part of their therapy. Another study in which patients
who received imatinib but were not subjected to
alloHSCT was carried out by the US Children’s’ On-
cology Group [20]. Patients with an upper age limit of
21 years were treated in cohorts with imatinib added to
chemotherapy, the final cohort receiving continuous
imatinib. AlloHSCT was only permitted on protocol
when a sibling donor was identified. This allowed
a comparison by treatment—those who received che-
motherapy in combination with imatinib but did not
proceed to alloHSCT and those who did. Interpreta-
tion was confounded by the relatively high rate of
off-protocol use of unrelated donor alloHSCT. How-
ever, at 3 years, the outcomes were not significantly
different for those treated with chemotherapy plus im-
atinib (N 5 25) compared to those treated with al-
loHSCT (N 5 21). More than 85% of patients were
alive and disease free at 3 years without alloHSCT.
The study was not designed or powered to ask thequestion of whether imatinib/chemotherapy could re-
place sibling alloHSCT for children with Ph 1 ALL
but the data are provocative and open the way for fur-
ther discussion.
TheUKALL12/ECOG2993 study reported in ab-
stract form also contains a large cohort of patients who
were treated with imatinib and chemotherapy and who
did not receive alloHSCT, in whom the 3-year OS is
28%. By comparison, the 5-year OS of historic con-
trols in the preimatinib era was 19%. As the data ma-
ture it will become clearer whether this represents an
improved outcome based solely on adding imatinib
to therapy. The other group of studies in which imati-
nib was given without alloHSCT are those involving
older patients. Certainly, there are the same impressive
initial responses seen in the younger population, but
these responses have not been shown to result in
long-term DFS [22,23].CONCLUSION
Presently, myeloablative allogeneic stem cell
transplant is still warranted for adults with Ph1
ALL. No data to date suggest that a TKI, either alone
or in combination with chemotherapy, has consider-
ably increased the proportion of patients with ALL be-
coming long-term disease-free survivors. However,
this proposition has never been formally tested in
a study designed to answer that question. It is possible
that the major benefit of using TKI will be in accom-
paniment to transplant; first, to allow a greater propor-
tion of patients to receive allogeneic HSCT, and
second to provide a sufficient level of posttransplant
disease suppression to allow time for a graft-versus-
leukemia effect to eliminate residual ALL in those
who enter transplant in a setting of persistent minimal
residual disease that is not eradicated by the condition-
ing therapy.With the expanded application of RIC for
S88 Biol Blood Marrow Transplant 17:S84-S88, 2011A. K. FieldingALL transplants and their use in an older patient pop-
ulation, this situation is increasingly likely. The first
patient group in whom omission of transplant is likely
to be tested will be in children, because in younger pa-
tients there is a better outcome to treatment with che-
motherapy alone, and younger individuals have more
to lose by risking the long-term adverse consequences
of allogeneic HSCT. However, because Ph1 ALL is
rare in children, the question of whether HSCT can
be a dispensable part of their therapy may not be an-
swered for some time.
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